NeuroVive establishes subsidiary in Lyon and extends collaboration with HCL

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has
established a subsidiary in Lyon, France. The establishment is part of a process
of extending its ongoing collaboration with Hospices Civils de Lyon (HCL) and
Professor Michel Ovize (the OPeRa program) to include drug development for the
treatment of stroke. The creation of a legal entity in France also coincides
with preparations for the potential commercialization of the company’s product
CicloMulsion®.
NeuroVive is party to an ongoing collaboration with Hospices Civils de Lyon
(HCL) and Professor Michel Ovize (the OPeRa program), which has focused on
cardiovascular disease to date. The establishment of a French subsidiary,
NeuroVive France, increases NeuroVive’s presence in the country while
simultaneously extending the partnership with HCL to include drug development
for the treatment of stroke.

The extended collaboration gives NeuroVive unique access to models for pre
-clinical testing of new drug candidates as well as competencies in various
types of reperfusion injury that are key clinical problems in acute medical
conditions such as myocardial infarct and stroke. NeuroVive also stands to
benefit from this expertise within the framework of its recently announced
collaboration with Isomerase Therapeutics on the development of the NVP014
project, which now becomes closely linked with the extended partnership with
HCL.

The establishment of a French subsidiary enables NeuroVive to participate as an
industrial partner in applications for national funding in France (RHU grants).
An application for close to EUR 10 m in funding during a five-year period which
includes NeuroVive alongside HCL and other industrial partners has already been
submitted. NeuroVive expects the outcome of the application to be announced
during the fall. There is a risk that the application can be dismissed and that
the consortium does not receive any funding.

At present, NeuroVive employs one person on a consultancy basis in Lyon, who
primarily handles contacts with HCL and the work associated with the CIRCUS
study. Should funding be allocated, either from the current or future
applications for national or international funds, NeuroVive intends to employ
research staff on a project basis for the extended stroke program in order to
complete pre-clinical and clinical trials.

“The extended collaboration between NeuroVive and HCL to include drug
development for the treatment of stroke gives us a great opportunity to benefit
even more from on the resources and contact network we’ve gained access to
through the OPeRa program. The timing of the establishment of our French
subsidiary is also optimal considering NeuroVive’s French operations. The
initial results from the CIRCUS study are expected in the third quarter 2015,
and NeuroVive needs a French legal entity ahead of potential commercialization
in France,” commented NeuroVive’s CEO Mikael Brönnegård.

About NeuroVive
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, is
developing a portfolio of products to treat acute cardiovascular and
neurological conditions through mitochondrial protection. These medical
conditions are characterized by a pressing medical need and have no approved
pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion®
(myocardial infarct) and NeuroSTAT® (traumatic brain injury) are currently being
evaluated in phase III and phase II studies, respectively. NeuroVive’s research
programs also include products for the treatment of brain cell injury in stroke
patients, and drug candidates for cellular protection and treating mitochondria
-related energy regulation diseases. NeuroVive’s shares are listed on NASDAQ
OMX, Stockholm, Sweden.

For Investor Relations and media questions, please contact:
Ingmar Rentzhog, Laika Consulting, Tel: +46 (0)46 275 62 21 or ir@neurovive.se.
It is also possible to arrange an interview with NeuroVive’s CEO Mikael
Brönnegård or COO Jan Nilsson at the above contact.

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden, Tel: +46 (0)46 275 62 20 (switchboard),
Fax: +46 (0)46 888 83 48, info@neurovive.se, www.neurovive.se

NeuroVive Pharmaceutical AB (publ) is required to publish the information in
this news release under The Swedish Securities Market Act. The information was
submitted for publication on 20 April, 2015, at 8.30 a.m. CET.
NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine company. The
company is listed on NASDAQ OMX Stockholm, Small Cap, under the ticker symbol
NVP. The share is also traded on the OTC market in the US. NeuroVive
Pharmaceutical (OTC: NEVPF) trades on the OTC Grey Market. Investors can find
Real-Time quotes and market information for the company
at www.otcmarkets.com/stock/NEVPF/quote (http://htt://www.otcmarkets.com/stock/N
E 
VPF/quot)